** Shares of Orthocell Ltd rise as much as 10.4% to A$0.53, their highest since Dec 17, 2021
** Biotechnology firm says it has received a regulatory approval from the Health Sciences Authority in Singapore
** Co says approval is for OCC to commence sales of its nerve repair product, Remplir, in Singapore
** Adds, it is on track to receive U.S. FDA regulatory clearance in Q1 CY25
** OCC stock up 17.1% YTD
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.